0001759138-26-000010
SEC filingCabaletta Bio, Inc. announced financial results for the fourth quarter and full year ended December 31, 2025, with research and development expenses of $36.2 million and $142.7 million, respectively, and cash, cash equivalents and short-term investments of $133.6 million as of December 31, 2025. The company provided business updates on rese-cel clinical programs, including myositis registrational cohort enrollment and upcoming data presentations in 1H26.